[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.240.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

December 2019 - April 2015

Decade

Year

Issue

June 2016, Vol 2, No. 6, Pages 703-839

Original Investigation

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer

Abstract Full Text
free access has multimedia has audio
JAMA Oncol. 2016;2(6):730-736. doi:10.1001/jamaoncol.2015.5941

This study describes the use of BRCA testing and evaluates how concerns about genetic risk and use of genetic information affect subsequent treatment decisions in young women with breast cancer.

Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):737-743. doi:10.1001/jamaoncol.2015.5536

This study compares the use of digital mammography with digital breast tomosynthesis for breast cancer screening and assesses the outcomes in a population as well as at individual levels in patients from an urban, academic breast center.

Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):744-750. doi:10.1001/jamaoncol.2015.6479

This analysis of 82 Oncologic Drugs Advisory Committee (ODAC) meeting transcripts explores the association between ODAC recommendations, ODAC members’ financial conflicts of interest, and approval of new oncologic drugs by the US Food and Drug Administration.

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):751-760. doi:10.1001/jamaoncol.2015.6113

This meta-analysis of 36 randomized clinical trials and cohort studies of 5768 patients with HER2-positive breast cancer investigates the association between pathologic complete response to therapy and time to recurrence and death.

Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer

Abstract Full Text
free access has multimedia has audio
JAMA Oncol. 2016;2(6):762-769. doi:10.1001/jamaoncol.2015.6396

This population-based study examines the potential benefits of aspirin use for prevention of overall cancer and specific cancers in 2 US population cohorts of health care professionals from 1980 to 2012.

Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):772-779. doi:10.1001/jamaoncol.2015.6315

This analysis of 1800 clinical trials in advanced solid tumors identifies circumstances in which a high objective response rate is associated with regulatory approval and therefore might be an appropriate end point for definitive single-arm studies of anticancer therapies.

Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):782-789. doi:10.1001/jamaoncol.2015.6339

This single-center study assessed the association of body composition with survival and locoregional control in a population of patients undergoing radiotherapy for head and neck squamous cell carcinoma.

Brief Report

Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):790-793. doi:10.1001/jamaoncol.2016.0004

This case series reviews the long-term use of romidepsin in patients with cutaneous T-cell lymphoma who received a maintenance dose-sparing regimen.

Research Letter

Cancer Communication in the Social Media Age

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):822-823. doi:10.1001/jamaoncol.2015.5475

Effective use of Twitter might be one way to communicate with the public about cancer clinical trials and increase awareness and enrollment.

Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):823-826. doi:10.1001/jamaoncol.2015.6587

This study examines the association of human papillomavirus genotype with survival in patients with head and neck squamous cell carcinoma.

Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):826-828. doi:10.1001/jamaoncol.2016.0016

This study explores the impact of BIM polymorphism on treatment outcome of patients with advanced adenocarcinoma, comparing those who experienced primary resistance with those who had partial response after treatment with epidermal growth factor receptor tyrosine kinase inhibitors.

Review

Natural Language Processing in Oncology: A Review

Abstract Full Text
JAMA Oncol. 2016;2(6):797-804. doi:10.1001/jamaoncol.2016.0213

This narrative review explores methods and potential limitations of different natural language processing strategies to foster collaborative efforts that can lead to advancements in cancer care.

Prognostic and Predictive Value in KRAS in Non–Small-Cell Lung Cancer: A Review

Abstract Full Text
JAMA Oncol. 2016;2(6):805-812. doi:10.1001/jamaoncol.2016.0405

This systematic review discusses current advancements in understanding the prognostic and predictive value of KRAS in non–small-cell lung cancer and attempts to explain the treatment advancements in both preclinical and clinical settings.

JAMA Oncology Clinical Challenge

A Seemingly Solitary Bone Lesion

Abstract Full Text
JAMA Oncol. 2016;2(6):815-816. doi:10.1001/jamaoncol.2016.1068

A white woman in her 60s with a medical history of multiple joint replacements related to osteoarthritis presented with left leg pain; a plain radiograph of the left femur showed a 15-cm area of moderate destruction in the proximal femoral shaft extending distally from the level of the lesser trochanter. What is your diagnosis?

Viewpoint

No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data

Abstract Full Text
JAMA Oncol. 2016;2(6):717-718. doi:10.1001/jamaoncol.2016.0075

This Viewpoint argues against universal tumor sequencing.

Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis

Abstract Full Text
JAMA Oncol. 2016;2(6):719-720. doi:10.1001/jamaoncol.2016.0078

This Viewpoint argues for universal tumor sequencing.

Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?

Abstract Full Text
JAMA Oncol. 2016;2(6):721-722. doi:10.1001/jamaoncol.2016.0094

This Viewpoint discusses the optimal duration of imatinib as adjuvant therapy for gastrointestinal stromal tumors.

From the JAMA Network

Tumor-Treating Fields—A Fundamental Change in Locoregional Management for Glioblastoma

Abstract Full Text
JAMA Oncol. 2016;2(6):813-814. doi:10.1001/jamaoncol.2016.0081

This commentary argues on behalf of alternating electromagnetic fields, or tumor treating fields (TTFs), to treat certain cancers and states that TTFs may eventually be integrated into management paradigms for a variety of tumors and clinical scenarios

Editorial

Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer

Abstract Full Text
JAMA Oncol. 2016;2(6):723-724. doi:10.1001/jamaoncol.2015.5975

Digital Breast Tomosynthesis: A Brave New World of Mammography Screening

Abstract Full Text
JAMA Oncol. 2016;2(6):725-727. doi:10.1001/jamaoncol.2015.5569

Evaluation and Regulation of Oncology Drug Approval: Finding the Right Balance

Abstract Full Text
JAMA Oncol. 2016;2(6):728-729. doi:10.1001/jamaoncol.2015.6477
Invited Commentary

The Neoadjuvant Model and Complete Pathologic Response in Breast Cancer: All or Nothing?

Abstract Full Text
JAMA Oncol. 2016;2(6):760-761. doi:10.1001/jamaoncol.2015.6509

Aspirin for Cancer Prevention: One Step Closer

Abstract Full Text
JAMA Oncol. 2016;2(6):770-771. doi:10.1001/jamaoncol.2015.6395

Response Rate as an Approval End Point in Oncology: Back to the Future

Abstract Full Text
JAMA Oncol. 2016;2(6):780-781. doi:10.1001/jamaoncol.2015.6352

Romidepsin Therapy Over 5 Years in a Clinical Setting—Real-world Experience

Abstract Full Text
JAMA Oncol. 2016;2(6):794-795. doi:10.1001/jamaoncol.2016.0072
JAMA Oncology Patient Page

Leptomeningeal Metastases

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):839. doi:10.1001/jamaoncol.2015.3502
Poetry and Oncology

The Permanent

Abstract Full Text
JAMA Oncol. 2016;2(6):743. doi:10.1001/jamaoncol.2016.1393
Comment & Response

Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia

Abstract Full Text
JAMA Oncol. 2016;2(6):828-829. doi:10.1001/jamaoncol.2016.1005

Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia—Reply

Abstract Full Text
JAMA Oncol. 2016;2(6):829. doi:10.1001/jamaoncol.2016.1011

Women at a Disadvantage in Fluorouracil Treatment

Abstract Full Text
JAMA Oncol. 2016;2(6):829-830. doi:10.1001/jamaoncol.2016.1086

Women at a Disadvantage in Fluorouracil Treatment—Reply

Abstract Full Text
JAMA Oncol. 2016;2(6):830-831. doi:10.1001/jamaoncol.2016.1089

Cachexia in Radiotherapy-Treated Patients With Head and Neck Cancer: A Phenomenon That Should Be Investigated

Abstract Full Text
JAMA Oncol. 2016;2(6):831. doi:10.1001/jamaoncol.2016.1387

Cachexia in Radiotherapy-Treated Patients With Head and Neck Cancer—Reply

Abstract Full Text
JAMA Oncol. 2016;2(6):831-832. doi:10.1001/jamaoncol.2016.1458

Against “Healthy Paternalism” at the End of Life

Abstract Full Text
JAMA Oncol. 2016;2(6):832. doi:10.1001/jamaoncol.2016.1390

Against “Healthy Paternalism” at the End of Life—Reply

Abstract Full Text
JAMA Oncol. 2016;2(6):833. doi:10.1001/jamaoncol.2016.1490
Correction

Error in Breast Cancer Detection Rate

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):833. doi:10.1001/jamaoncol.2016.0633
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):709. doi:10.1001/jamaoncol.2015.3513
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2016;2(6):703. doi:10.1001/jamaoncol.2015.3512
×